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SPECIAL FOCUS: STRATEGIC DIRECTIONS
IN MUSCULOSKELETAL TISSUE ENGINEERING*
Induced Remodeling of Porcine Tendons to Human
Anterior Cruciate Ligaments by a-GAL Epitope
Removal and Partial Cross-Linking
Kevin R. Stone, MD,1 Ann Walgenbach, RN,1 and Uri Galili, PhD2
This review describes a novel method developed for processing porcine tendon and other ligament implants that
enables in situ remodeling into autologous ligaments in humans. The method differs from methods using extra-
cellular matrices (ECMs) that provide postoperative orthobiological support (i.e., augmentation grafts) for healing
of injured ligaments, in that the porcine bone-patellar-tendon-bone itself serves as the graft replacing ruptured
anterior cruciate ligament (ACL). The method allows for gradual remodeling of porcine tendon into autologous
human ACL while maintaining the biomechanical integrity. The method was first evaluated in a preclinical model
of monkeys and subsequently in patients. The method overcomes detrimental effects of the natural anti-Gal
antibody and harnesses anti-non-gal antibodies for the remodeling process in two steps: Step 1. Elimination of a-gal
epitopes—this epitope that is abundant in pigs (as in other nonprimate mammals) binds the natural anti-Gal
antibody, which is the most abundant natural antibody in humans. This interaction, which can induce fast resorption
of the porcine implant, is avoided by enzymatic elimination of a-gal epitopes from the implant with recombinant
a-galactosidase. Step 2. Partial cross-linking of porcine tendon with glutaraldehyde—this cross-linking generates
covalent bonds in the ECM, which slow infiltration of macrophages into the implant. Anti-non-gal antibodies are
produced in recipients against the multiple porcine antigenic proteins and proteoglycans because of sequence
differences between human and porcine homologous proteins. Anti-non-gal antibodies bind to the implant ECM,
recruit macrophages, and induce the implant destruction by directing proteolytic activity of macrophages. Partial
cross-linking of the tendon ECM decreases the extent of macrophage infiltration and degradation of the implant and
enables concomitant infiltration of fibroblasts that follow the infiltrating macrophages. These fibroblasts align with
the implant collagen fibers and secrete their own collagen and other ECM proteins, which gradually remodel the
porcine tendon into human ACL. This ligamentization process lasts*2 years and the biomechanical integrity of
the graft is maintained throughout the whole period. These studies are the first, and so far the only, to demonstrate
remodeling of porcine tendon implants into permanently functional autologous ACL in humans.
Keywords: anterior cruciate ligament implants, porcine tendon, anti-Gal, anti-non-gal, xenotransplantation,
a-galactosidase
Introduction
Porcine extracellular matrix (ECM) implants ofdecellularized tissues and organs are the subject of
extensive research for biocompatible replacement of tis-
sues with impaired function in humans.1,2 Most porcine
ECMs studied in the area of ligament repair in orthopedic
surgery are ‘‘patches’’ or sheets of connective tissue ECMs
that are attached around the injured ligament to provide
orthobiological support, which decreases the in vivo me-
chanical forces on the ligament repair during postopera-
tive healing, prevents repair gap formation or failure, and
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improves host cell infiltration for the regeneration of the
injured tissue.3–7
We have been interested in determining whether the
porcine ligament tissue itself can be used as an implant that
undergoes remodeling and reconstruction into a functioning
autologous ligament after its grafting to replace ruptured
ligament in humans. In this review, we describe studies that
led to the successful development of a novel method for
processing of porcine bone-patellar-tendon-bone implants,
which enables the in situ conversion of the porcine tendon
grafts into functional autologous human anterior cruciate
ligaments (ACLs) while being constantly subjected to bio-
mechanical stress. The preclinical and clinical studies de-
scribed in this review on ACL reconstruction by porcine
tendon further suggest that processed porcine tendons and
ligaments may be used for reconstruction of other torn lig-
aments and tendons in orthopedic surgeries.
Treatments for Ruptured ACLs
Rupture of the ACL is a common injury. More than
200,000 damaged ACLs undergo surgical intervention in
the United States each year. The two techniques currently
practiced in such surgical interventions are bone-patellar-
tendon-bone ligament autograft harvested from the knee for
reconstructing the ACL, or cadaveric bone-patellar-tendon-
bone allografts. After the implantation of autograft or allo-
graft tendon, the implant undergoes a process of remodeling
called ‘‘ligamentization’’.8–12 In this process, the fibroblasts
within the implant become necrotic because of ischemia and
macrophages infiltrating the implant debride the necrotic
tissue and induce vascularization of the implant. Fibroblasts
of the recipient repopulate the implant and align with the
collagen fibers’ ‘‘scaffold.’’ These fibroblasts secrete col-
lagen and other ECM proteins ultimately resulting in grad-
ual remodeling of implant into an autologous tissue with
characteristic ACL structure.
The harvest of an autograft patellar tendon from the knee
often results in increased pain, because of a second surgical site,
longer recovery periods, and increased morbidity. Complica-
tions may further include patella fracture, patellar tendon rup-
ture, and scar formation.12,13 Cadaveric tendon allografts offer a
limited source of ACL replacement tissue because of scarcity of
available tissue from young, healthy donors. Allografts from
elderly cadavers might be of significant lower biomechanical
capacity than allograft from young cadaveric donors. The per-
ceived risk of transmission of hepatitis and other infectious
diseases is another obstacle to the acceptance of cadaveric tissue.
In view of the disadvantages and risks in use of tendon au-
tografts or allografts for ACL reconstruction, we have explored
the possible use of porcine patellar tendon implants that are
transplanted according to the methods using autologous or al-
logeneic tendon for ACL reconstruction. If successful, porcine
patellar tendon may serve as a limitless source of implants of
standardized age and size thereby assuring quality of the implant,
as it will be harvested from pigs of optimal age. In addition,
sterility of the graft will be controlled by rigorous sterilization.
Considerations in Using Porcine Tendon
Implants in Humans
The immune system in nonhuman primates and in humans
reacts against porcine implant grafts, except for grafts con-
structed of collagen, a protein with low immunogenicity.14–16
This immune response induces extensive infiltration of mac-
rophages that cause proteolytic degradation of the implant.16
To enable in situ gradual remodeling and regeneration of
porcine tendon into autologous human ACL, while main-
taining biomechanical function of the graft, the anti-implant
immune response in the recipient has to be attenuated. Such
attenuation is required to slow the immune-mediated de-
struction of the implant. In addition, the ligament implant
fibers, comprising collagen and other ECM proteins, should
be partially cross-linked to retain the biomechanical capacity
of the ligament implant throughout the period of ligamenti-
zation, that is, destruction of the implant and its concomitant
repopulation and regeneration by the recipient’s fibroblasts
that produce the autologous ECM. Such cross-linking would
further slow the implant destruction by slowing the infiltration
of macrophages, thereby allowing for fibroblasts to follow
these macrophages, align with the porcine collagen fibers, and
secrete autologous ECM for the remodeling of the implant. As
detailed hereunder, attenuation of the immune response to the
porcine graft was achieved by incubation of the porcine ten-
don in a solution of recombinant a-galactosidase followed by
partial cross-linking with glutaraldehyde.
Preclinical Studies in Monkeys
As a first stage in this research, we used rhesus monkeys
as the experimental primate model. Our objectives have
been to determine in this model the optimal conditions for
engineering pig tendon to be used for ACL reconstruction to
further perform a clinical trial for evaluating safety and
efficacy of such implants in patients with ruptured ACL.
The rhesus monkey was chosen as a model because it pro-
duces the natural anti-Gal antibody like humans.17
Anti-Gal response in implant recipients
Anti-Gal is the most abundant natural antibody in humans,
comprising *1% of circulating immunoglobulins18–21 and
binding specifically to a mammalian carbohydrate antigen
called the a-gal epitope with the structure Gala1-3Galb1-
4GlcNAc-R.22 This epitope is abundant on glycolipids,
glycoproteins, and proteoglycans of nonprimate mammals,
including pigs, prosimians, and New World monkeys.17,23,24
In contrast, the a-gal epitope is completely absent in Old
World monkeys, apes, and humans; instead, these primates
and humans produce the natural anti-Gal antibody in large
amounts.17,19,23,24 As many as 1% of human B cells are ca-
pable of producing anti-Gal.25 Most of these B cells (desig-
nated anti-Gal B cells) are quiescent.25 In contrast, anti-Gal B
cells along the gastrointestinal tract continuously produce
anti-Gal against carbohydrate antigens presented on bacteria
of the normal gastrointestinal flora.26,27 Similar to other
nonprimate mammals, the a-gal epitope is present in large
amounts in most pig tissues, including patellar tendons where
it is found as*1 · 1011 epitopes/mg.28
Several studies demonstrated in primates the immune re-
sponse against loose connective tissue ECM such as swine
intestinal submucosa (SIS)29 and decellularized dermis.30 For
determining anti-Gal response in monkeys against porcine
tendon, an untreated porcine tendon with one bone plug was
implanted across the knee joint of a rhesus monkey to replace
the autologous ACL. The porcine tendon was implanted
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within tunnels drilled in the femur and tibia, anchored in the
femur end by the bone plug, and sutured at the free end to the
tibia.31 Monitoring the immune response in rhesus monkey
recipient demonstrated a *1000-fold increase in anti-Gal
titer within 2 weeks, as measured by ELISA with synthetic
a-gal epitopes linked to bovine serum albumin (a-gal BSA)
as solid-phase antigen (Fig. 1).31 This elicited anti-Gal re-
sponse results from activation of the many quiescent anti-Gal
B cells by glycoprotein-linked a-gal epitopes released from
the implant. A similar extensive anti-Gal response was ob-
served in humans receiving xenograft cells expressing a-gal
epitopes, even under strong immunosuppression.32,33 The
combined activities of the natural and elicited anti-Gal anti-
bodies exacerbate the detrimental effects of this antibody
because of its effective binding to the multiple a-gal epitopes
in the porcine implant, rapid recruitment of macrophages by
complement chemotactic factors generated after anti-Gal/a-
gal epitopes interaction,34,35 and binding of macrophages to
the ECM after Fc/Fc receptor interaction36 with anti-Gal
bound to the implant.37 Macrophages further bind through
their C3b receptors to C3b complement deposits on ECM.38
Macrophages infiltrating into xenogeneic ECM implants
were shown to release proteases that degrade the implant.39
Within the untreated porcine tendon implant, multiple re-
cruited macrophages mediated its complete resorption
within a period of 2 months (Fig. 1).31 A similar elevation
of anti-Gal activity and anti-Gal-mediated resorption of
implanted orthopedic tissue was observed in monkeys
implanted with porcine cartilage containing a-gal epi-
topes.40–42 Thus, we concluded that a prerequisite for
successful implantation of porcine dense connective tissue
ECM implants in humans is the elimination of a-gal epi-
topes from the implant. This conclusion is supported by
observations demonstrating a higher efficacy of porcine
dermis ECM implanted in monkeys when the ECM was
devoid of a-gal epitopes, in comparison with porcine der-
mis ECM expressing a-gal epitopes.30 It should be noted
that studies with SIS implants in monkeys and in anti-Gal-
producing mice demonstrated no detrimental effects of
anti-Gal on implantation of SIS whether or not the SIS had
a-gal epitopes.14,43,44 The reason for these differences is
the very low concentration of a-gal epitopes on SIS. Be-
cause of relatively ‘‘great distance’’ between such epitopes
on SIS, the detrimental effects of anti-Gal seem to be
marginal. However, the high concentration of a-gal epi-
topes in porcine tendons is detrimental upon implantation
and requires the removal of this carbohydrate antigen.
Complete elimination of a-gal epitopes from the dense con-
nective tissue of porcine ligaments was achieved by incubation
for 12–14h in a solution of recombinant a-galactosidase.28 A
similar effective elimination of a-gal epitopes by recombinant
a-galactosidase was demonstrated with porcine cartilage.42 The
gene for this enzyme was cloned from coffee beans and ex-
pressed in yeast Pichia pastoris expression system.45,46 Re-
combinanta-galactosidase cleaves the terminal galactosyl of the
a-gal epitopes, thus preventing subsequent binding of anti-Gal
to the remaining portion of the carbohydrate chain with the
structure Galb1-4GlcNAc-R.28
Anti-Gal response in monkeys implanted with porcine
tendon depleted of a-gal epitopes and partially cross-linked
with glutaraldehyde (see next section) was*100-fold lower
than that in the recipient of the untreated tendon (Fig. 1).
The 10- to 20-fold increase in anti-Gal activity, observed
after 2 weeks, is the result of an immune response against a-
gal epitopes on red cells and bone marrow cells enclosed
within cancellous bone cavities in the bone plug, which were
not accessible to a-galactosidase. Glycoproteins carrying a-
gal epitopes that were released from these cells stimulated
quiescent anti-Gal B cells to produce this antibody.28 Most of
this anti-Gal response diminishes after 3 months because, by
that time, the bone plug of the implant is almost completely
remodeled into autologous bone and thus the source of gly-
coproteins with a-gal epitopes is eliminated.28
Cross-linking of tendon tissue with glutaraldehyde
a-Galactosidase-treated tendons further underwent partial
cross-linking by glutaraldehyde to strengthen the biome-
chanical capacity of the tendon implant, thus avoiding tearing
during in situ remodeling of the implant.28,31 Glutaraldehyde
molecule has two aldol groups- CHO(CH2)3CHO which co-
valently interact with amino groups of proteins and thus cross-
links between proteins. These covalent bonds function as an
obstacle, slowing the infiltrating macrophages. Glutaraldehyde
cross-linking is widely used in processing of porcine heart
valves for replacement of functionally impaired human heart
valves. Incubation of porcine heart valves for days in 0.25%
glutaraldehyde results in maximum cross-linking that blocks
any infiltration of macrophages and of other inflammatory
cells into the implanted heart valve. Therefore, heart valve
implants do not undergo remodeling. Because of the extensive
cross-linking, macrophages do not penetrate the implanted
porcine valves and the detrimental deposits of these macro-
phages accumulate on the surface of the valve leaflets.47,48
It was reasonable to assume that, to enable remodeling
of porcine tendon implants into autologous ACL, the cross-
linking should be only partial, at a level that slows the
destruction of implants but does not completely prevent in-
filtration of macrophages into the implant.28,31 This macro-
phage infiltration is required for allowing the gradual
destruction of the implant at a pace slow enough to allow the
recipient’s fibroblasts to follow these macrophages. These
FIG. 1. Anti-Gal and anti-non-gal IgG titers in rhesus
monkeys implanted with porcine tendon for ACL recon-
struction.:, anti-Gal after implantation of untreated porcine
tendon; C, anti-Gal after implantation of engineered tendon;
-, anti-non-gal after implantation of engineered tendon.
Error bars represent standard deviation of reciprocal titers
(modified from Ref.,31 with permission). ACL, anterior
cruciate ligament.
414 STONE ET AL.
infiltrating fibroblasts are expected to align with the porcine
collagen fibers and secrete their collagen, thereby remodeling
the porcine ligament implant into an autologous ACL. Opti-
mal cross-linking was determined empirically by incubation
of a-gal-devoid patellar tendons in various concentrations of
glutaraldehyde solution for 12 h. Subsequently, the tendons
were washed and incubated for 24 h in a 0.1M glycine solu-
tion, to block any free active aldol groups of glutaraldehyde.31
Tendons lacking a-gal epitopes, incubated in 0.01%
glutaraldehyde, were washed and implanted as ACL re-
placement in rhesus monkeys. Histological study of the
implants after 2 months indicated that they were filled with
large number of macrophages that induced extensive de-
struction of the xenograft. In contrast, tendons incubated in
0.25% glutaraldehyde displayed only marginal infiltration of
macrophages, insufficient for remodeling, because of very
high cross-linking. However, incubation in 0.1% glutaral-
dehyde was found to result in optimal levels of macrophage
infiltration; therefore, this concentration was chosen for use
in engineering of porcine tendon for implantation.31 The
processed tendons were incubated with glycine for 24 h,
irradiated by 17.8 kGy of e-Beam for final sterilization, and
stored frozen until implantation. In vitro biomechanical
stress tests indicated that this cross-linking of porcine ten-
dons did not affect their biomechanical characteristics (un-
published observations).
Implantation studies in monkeys
A study was performed in 20 rhesus monkeys to evaluate
the feasibility of the pig tendon devoid of a-gal epitopes and
partially cross-linked as an ACL reconstruction implant.31
Testing involved a unilateral monkey ACL reconstruction
model with 2, 6, and 12 month sacrifice time points and
clinical, histological, and biomechanical assessments. Mon-
keys receiving an allograft tendon for ACL reconstruction
served as control. All animals returned to normal function by
7 weeks postoperatively. Range of motion and laxity were
assessed by manual manipulation and comparison with
contralateral, unoperated limbs. All range of motion and
laxity measurements performed after 6 and 12 months were
clinically acceptable, considering the surgical and anatomi-
cal complexities of the small primate knee. No clinically
significant differences between allograft and treated porcine
implants were noted in either clinical end point.31
In addition to anti-Gal activity measurements already
described, serology studies assessed anti-non-gal antibodies
production by the monkey recipients at various time points.
These were measured by ELISA in which the solid-phase
antigen was a homogenate of porcine tendon containing
microscopic size fragments that was dried and thus adhered
to ELISA wells as 2mg/mL. The serum in this assay was
depleted of anti-Gal before the assay by adsorption on
glutaraldehyde-fixed rabbit red cells.28 Anti-non-gal anti-
body activity peaks 3–6 months postimplantation because of
the immune response against the multiple immunogenic
proteins of the pig implant (Fig. 1).31 This immunogenicity
is caused by the many differences in amino acid sequences
between most homologous proteins in pigs and primates.
These differences result in production of antibodies, called
anti-non-gal antibodies, against most porcine proteins.15,16
The activity of these antibodies decreases by 9 and 12
months because much of the original porcine tissue causing
immunological stimulation for production of anti-non-gal
antibodies was eliminated at that time (Fig. 1).31
Necropsy in recipients of the processed porcine tendon
implant demonstrated no degenerative articular cartilage
changes in operative limbs, normal synovium healing, and
normal ligament morphology.31 Histological evaluation of
implants in both rhesus monkeys implanted with engineered
porcine tendon and in control recipients of rhesus monkey
allograft ligament revealed remodeling, leading to a gradual
replacement of the initially engrafted matrix with host fi-
broblast and collagen, as well as advanced implanted tendon
and bone integration in host bone tunnels. Postmortem
ex vivo biomechanics analysis of the implants indicated that
the ligamentized implants were not significantly different
compared with the primate allograft cohort and compared
favorably with various published values for autograft re-
constructions in animals. The ligamentized-treated implants
at both 6 and 12 months31 either equaled or exceeded the
published strength of these autograft reconstructions per-
formed in various animal models including primates.49–52
These observations in monkeys prompted us to perform a
clinical trial on replacement of ruptured ACL with en-
gineered porcine bone-patellar- tendon-bone implants.
Implantation of Engineered Porcine
Tendons in Patients
Porcine patellar tendons were treated for 12 h with
a-galactosidase, washed, partially cross-linked for 12 h with
0.1% glutaraldehyde, washed, blocked with 0.1M glycine,
and sterilized by irradiation with e-Beam (Fig. 2). These en-
gineered tendons were studied as implants in patients who
ruptured their ACL. This Phase I clinical trial was performed
as an Food and Drug Administration (FDA)-approved single-
center feasibility clinical study of the treated xenograft in 10
subjects in accordance with U.S. FDA Investigational Device
Exemption and good storage practice requirements.28 The
study protocol was approved by an institutional review board
FIG. 2. Engineered ligament derived from porcine bone-
patellar-tendon-bone implant.
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and all subjects provided written informed consent. The study
objectives were verification of graft implantability, technical
feasibility, and safety.
Of six evaluable subjects, five presented with func-
tional implants at the 24-month postoperative time point
and satisfied all study success criteria, including effusion,
KT-1000, Pivot Shift, Lachman’s and Anterior Drawer
tests, as well as all safety parameters.28 The remaining
subject, who was the only serious adverse event deter-
mined to be graft related, presented with tibia bone plug
loosening at 15 months post ACL reconstruction and had
his implant removed and tibial tunnel grafted with can-
cellous patellar tendon allograft. Four subjects were
nonevaluable because of nondevice-related complications
during the study because of trauma and very early return
to sports.28 None of the patients displayed any indication
of toxicity parameters in complete blood count (CBC),
blood chemistry, and serology, as well as in urine
chemistry at the 24-month time point of the study.
Analysis of anti-Gal IgG antibody activity demonstrated
low increase that peaked at 2 months. This could be best
demonstrated by comparison of anti-Gal binding to a-gal
BSA in ELISA in sera diluted 1:640, assayed at the various
time points.28 Anti-Gal activity in two representative patients
is presented in Figure 3A. On average, the preimplantation
titer of anti-Gal was 1:200, and 2 months postimplantation, it
increased only to*1:1000, then 6 months postimplantation,
it decreased to *1:700 (not shown). This low increase in
anti-Gal response reflects the activation of quiescent anti-
Gal B cells by glycoproteins carrying a-gal epitopes re-
leased from porcine bone marrow cells and red blood cells
within the cancellous bone cavities of the implant. Anti-Gal
returned to preimplant range by 12 months, reflecting the
completion of the bone blocks remodeling process of the
porcine bone into human bone. Anti-non-gal IgG response
appeared after 2 months, peaked at *6 months, and re-
solved to preimplant range by 24 months (Fig. 3B).28 These
observations suggest that at*2 years postimplantation, the
porcine tissue within the implant completed the liga-
mentization process and was replaced by nonimmunogenic
host fibroblasts, producing collagen fibers and other ECM
components.
The diversity of anti-non-gal antibodies in tendon implant
recipients could be demonstrated by Western blot analysis.
FIG. 3. Anti-Gal (A) and anti-non-gal IgG antibody response (B) in two representative orthopedic patients implanted with
engineered pig patellar tendon for the replacement of ruptured ACL. Patient 1, open columns; Patient 2, closed columns.
Anti-Gal antibody activity was determined by ELISA with a-gal linked to bovine serum albumin as solid-phase antigen.
Anti-non-gal antibody activity was determined with anti-Gal-depleted sera (adsorption on glutaraldehyde-fixed rabbit red
cells), by ELISA with homogenate of fragmented pig tendon as solid-phase antigen. The figure shows antibody binding at
serum dilution of 1:640 (based on data presented in Ref.28).
FIG. 4. Anti-non-gal antibody analysis by Western blots
with porcine patellar tendon and kidney proteins or human
tendon proteins separated on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. (A) Preimplantation
serum of patient P-10. (B) Serum of patient P-10, 6 months
postimplantation. (C) Serum of patient P-03, 6 months
postimplantation. In this analysis, the sera were depleted of
anti-Gal (as shown in Fig. 3) and were diluted 1:10 (mod-
ified from Ref.,28 with permission).
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Preimplantation and 6-month postimplantation sera were
depleted of anti-Gal antibody and studied for binding to
porcine tendon proteins separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and blotted on
nitrocellulose paper.28 As shown in Figure 4A, the patients
had no measurable antibody binding to pig tendon proteins
in the preimplantation sera. However, multiple antibodies
bound to a large variety of porcine tendon proteins, creating
a smear pattern rather than individual lines, were observed
in postimplantation sera (Fig. 4B, C). These smear patterns
are the result of partial overlap between bands of proteins
of close size. Many of the porcine tendon proteins binding
anti-non-gal antibodies were also observed in Western blot
proteins of porcine kidney (Fig. 4B, C).28 The demonstra-
tion of these multiple antibodies is in accord with the no-
tion that most pig proteins are immunogenic in humans
because of 3–40% differences in the amino acid sequences
between pig and humans.15 These anti-non-gal antibodies are
highly specific to porcine proteins as indicated by the com-
plete lack of antibody binding to human ligament proteins
(Fig. 4B, C).28
Partial cross-linking of porcine tendons enabled conver-
sion of anti-non-gal antibodies from antibodies inducing
rapid macrophage mediated destruction of untreated tendon
tissue into beneficial antibodies that mediate gradual re-
modeling of the pig tendon implant into an autologous ACL.
The rapid destruction of untreated tendon, or of tendons
under suboptimal processing, could be inferred from the
extensive infiltration of macrophages that destroy prema-
turely the implant after cross-linking with 0.01% glutaral-
dehyde.31 In tendon implants that were cross-linked with the
optimal glutaraldehyde concentration of 0.1%, anti-non-gal
antibodies binding to the tendon proteins also were likely to
recruit macrophages by activating the complement system
and generating complement cleavage chemotactic factors, as
in most antigen–antibody interactions. The recruited mac-
rophages further bind to the Fc portion of the anti-non-
gal antibodies immunocomplexed to the implant, secrete
their proteases, and thus cause degradation of the porcine
ECMs. However, because of the cross-linking, penetration
of macrophages is slowed, enabling fibroblasts that follow
the infiltrating macrophages to align with the porcine scaffold
of collagen fibers and secrete their own ECMs, as shown in
Figure 5.28 Ligamentization of the implant into human ACL,
within a period of *2 years, results in formation of a non-
immunogenic autologous ACL and thus, it may be functional
for life without being subjected to a chronic anti-non-gal im-
mune response. Indeed, long-term monitoring of the five eva-
luable patients has indicated that the porcine ligament implants
are continuing to function as autologous ACL for >10 years.
The ligamentization process could be histologically ob-
served in porcine tendon implants that were explanted from
five of the patients, by secondary surgical intervention, due
primarily to sport injuries (Fig. 5).28 Processed porcine tendons
mainly contain the collagen fibers bioscaffold and the associ-
ated matrix proteins and proteoglycans (Fig. 5A). As already
indicated, anti-non-gal antibodies binding to the implant are
likely to contribute to the observed infiltration of macrophages
into the transplanted porcine tendon by generating gradients
of chemotactic complement cleavage peptides such as C5a
and C3a (Fig. 5B). These infiltrating macrophages also secrete
cytokines,34 including vascular endothelial growth factor
(VEGF), which induce vascularization of the implant (Fig. 5C).
Recipient’s fibroblasts infiltrate the implant through newly
formed blood vessels and align with the porcine collagen fibers
scaffold (Fig. 5D). These fibroblasts secrete their own collagen
fibers and thus convert the implanted tendon into a viable au-
tologous ACL (Fig. 5E). The collagen fibers are further stained
blue in trichrome staining (Fig. 5F). To our knowledge, these
studies are the first, and so far the only, to demonstrate re-
modeling of porcine tendon implants into functional permanent
autologous ACL in humans.
FIG. 5. Histological demonstration of various ligamentization stages in patients implanted with processed porcine tendon.
(A) Porcine patellar tendon after processing for removal of a-gal epitopes and cross-linking by glutaraldehyde. (B)
Infiltration of macrophages into the implant. (C) Vascularization of the implant in a region near macrophage infiltrates. (D)
Repopulation of a section of the implant by fibroblasts that aligned with the collagen fibers. (E) An advanced stage of
ligamentization in which the repopulating fibroblasts are far apart from each other because of the collagen fibers and other
matrix proteins and proteoglycans that have been secreted by these cells. (F) Collagen fibers of the implant stained blue by
trichrome staining. (A–E): Hematoxylin and eosin, (F): trichrome ( · 200) (from Ref.,28 with permission).
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Conclusions
Porcine tendon and ligaments may be used as implants
that undergo remodeling to become autologous ligaments
in humans, if the immune response against such implants is
attenuated. Porcine bone-patellar- tendon-bone served as a
model in reconstruction of ruptured ACL. The porcine
tendons were processed for removal of a-gal epitopes by
recombinant a-galactosidase, followed by partial cross-
linking with glutaraldehyde. Studies in rhesus monkeys
demonstrated that implantation of such processed tendons,
for replacement of resected ACL, resulted in gradual li-
gamentization of the implant into autologous ACL. Sub-
sequent studies in humans demonstrated a similar process
of remodeling of the tendon implant into autologous ACL
within a period of *2 years, while the biomechanical in-
tegrity is maintained. It is suggested that other porcine
ligaments and tendons undergoing similar processing may
be considered as implants in humans as well.
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